Further, resveratrol, which increases SERCA2 activity, has been shown to decrease AF, suggesting that targeting SERCA2 activity may be a viable therapeutic approach (Bai et al., 2016; Chong et al., 2015). Here, ATP2A2 is linked to atrial fibrillation.